Latest Entitlement Offer News

Mirrabooka Investments Limited has launched a $85 million non-renounceable entitlement offer at $3.06 per share, inviting eligible shareholders to increase their holdings with a top-up facility. The offer aims to bolster the company’s investment capacity amid evolving market conditions.

Mirrabooka Investments Limited has announced a 1-for-7 entitlement offer priced at $3.06 per share, aiming to raise approximately $85 million to capitalize on emerging investment opportunities.

DTI Group Limited has announced a fully underwritten pro-rata entitlement offer to raise approximately $2.69 million, primarily aimed at repaying a $1.25 million loan from major shareholder Finico Pty Ltd. The offer opens on 13 May and closes on 10 June 2025, with new shares priced at $0.006 each.

Corella Resources has capitalised on strong demand following its recent rights issue by placing an additional 68 million shares and options, boosting total funds raised to over $1 million.

Redivium Limited has launched its Trading Division and secured key agreements as it pushes forward with European battery recycling projects, though funding challenges remain.

Alvo Minerals has extended the closing date for its pro-rata entitlement offer to 13 May 2025, giving shareholders additional time to subscribe to new shares and options. This move aims to support the company’s ongoing exploration ambitions in Brazil’s base and rare earth metals sectors.

Alvo Minerals has signed a non-binding LOI to acquire the Lavra Velha Gold-Copper Project with a 520koz gold resource, while progressing exploration at its Palma Copper-Zinc Project and launching a $4.4 million capital raise.

Jayride Group has appointed a new management team and raised $1.51 million to fund a major restructuring focused on halving operating costs and resolving supplier payment issues. Despite supply constraints, demand remains strong, positioning the company for a potential rebound.

Mighty Kingdom Limited reports a positive operating cash inflow and significant cost reductions in Q3 FY25, alongside leadership changes and a $3.35 million capital raise underway to fuel growth.

Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.

Tasman Resources has progressed its Lake Torrens IOCG joint venture with Fortescue, expanded geophysical surveys, and outlined plans for a multi-target drilling campaign at Parkinson Dam, supported by a $3.68 million entitlement offer.

Peak Minerals has completed a key phase of rutile exploration at its Minta Project in Cameroon, reporting promising heavy mineral findings and appointing a seasoned mining executive as CEO. The company also secured $2 million through a shareholder entitlement offer to fund ongoing activities.